senior global project head for hemophilia at Sanofi. Fitusiran can be stored at room temperature for a period and will be available in a pre-filled pens for some doses. That continence factor ...

Sanofi’s management has highlighted fitusiran, a potential competitor to Roche’s haemophilia A drug Hemlibra, as one of the most important drugs in its pipeline.

of adolescents and adults in the fitusiran group, compared to 17% with prior factor or BPA prophylaxis, said Sanofi. One issue dogging the programmes has been cases of blood clots in late-stage ...

Our focus on pipeline value delivered further growth for Sanofi with sales from launches of new medicines and vaccines growing by 46.5%. We obtained approval for Qfitlia (fitusiran), a new ...

In 2025, Plozasiran (Arrowhead Pharmaceuticals), Donidalorsen (Ionis Pharmaceuticals) and Fitusiran (Sanofi/Alnylam) are expected to receive approval. All of that is being driven by increasing ...

Sanofi confirms the expectation of a strong rebound in business EPS with growth at a low double-digit percentage at CER (before share buyback)6 • Sanofi intends to complete a share buyback program in ...

Sanofi: strong Q1 performance and 2025 guidance confirmed Paris, April 24, 2025 Q1 sales growth of 9.7% at CER1 and business EPS2 of €1.79 Pharma launches reached sales of €0.8 billion, up ...